Scribe Therapeutics Inc., a molecular engineering company, has raised $100 million in Series B financing. Avoro Ventures and Avoro Capital Advisors led the round with participation from other investors that included OrbiMed Advisors and Andreessen Horowitz.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: